Unique ID issued by UMIN | UMIN000013426 |
---|---|
Receipt number | R000015674 |
Scientific Title | Clinical study of combination therapy of adoptive immune-cell therapy with chemoradiothrapy for pancreatic cancer |
Date of disclosure of the study information | 2014/03/14 |
Last modified on | 2017/03/17 10:06:30 |
Clinical study of combination therapy of adoptive immune-cell therapy with chemoradiothrapy for pancreatic cancer
Clinical study of combination therapy of adoptive immune-cell therapy with chemoradiothrapy for pancreatic cancer
Clinical study of combination therapy of adoptive immune-cell therapy with chemoradiothrapy for pancreatic cancer
Clinical study of combination therapy of adoptive immune-cell therapy with chemoradiothrapy for pancreatic cancer
Japan |
pancreatic cancer (HLA type A2/A24)
Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery | Radiology |
Malignancy
NO
To evaluate the safety and efficacy about concurrent therapy of immune-cell therapy and chemoradiotherapy for pancreatic cancer
Safety,Efficacy
Pragmatic
Not applicable
disease-free rate
overall survival period
overall survival rate
Distant metastasis-free survival rete
Frequency and type of adverse events
QOL
immunological parameters
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine | Maneuver |
Radiation therapy
Gemcitabine
Alpha-Beta T-cell Therapy
20 | years-old | <= |
80 | years-old | >= |
Male and Female
(1)Patient with locally advanced pancreatic cancer without prior treatment
(2)Patient who can be treated with adoptive immune-cell therapy and chemoradiotherapy
(3)Patient with HLA A2 and/or A24
(4)Patient age of 20 to 80 years
(5)Patient with performance status 0-2
(6)Patient has more than three months of expected life time
(7)Patient with no serious abnormality in bone marrow, liver, and renal functions
(8)Patient agrees to participate in this study with informed consent
(1)Patient with interstitial pneumonia
(2)Patient with active autoimmune disease
(3)Patient with active heart disease
(4)Patient with uncontrolable infectious diseases
(5)Patient with serious drug allergy
(6)Patient with continuous use of systemic administration of steroids
(7)Patient in pregnancy
(8)Patient positive for HIV or HTLV-1
(9)patient who is inadequate to enter this study due to the other reasons by physician's judgments
10
1st name | |
Middle name | |
Last name | Takashi Nakano |
Gunma University
Department of Radiation Oncology, Gunma University Graduate School of Medicine
3-39-22 Showa-machi, Maebashi, Gunma 371-8511, JAPAN
027-220-8383
syoshi@gunma-u.ac.jp
1st name | |
Middle name | |
Last name | Yoshiyuki Suzuki |
Gunma University
Department of Radiation Oncology, Gunma University Graduate School of Medicine
3-39-22 Showa-machi, Maebashi, Gunma 371-8511, JAPAN
027-220-8383
syoshi@gunma-u.ac.jp
Gunma University
Medinet Co.,Ltd.
Profit organization
Seta Clinic Group
NO
群馬大学(群馬県)
2014 | Year | 03 | Month | 14 | Day |
Unpublished
Completed
2013 | Year | 10 | Month | 23 | Day |
2014 | Year | 04 | Month | 01 | Day |
2014 | Year | 03 | Month | 14 | Day |
2017 | Year | 03 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015674
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |